Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gedatolisib + FOLFIRI vs Bevacizumab + FOLFIRI in mCRC
NCT01937715Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Feb 2014
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of gedatolisib in colorectal cancer (metastatic) (mCRC), sponsored by Pfizer. Started Feb 2014; status: terminated.
02
Drugs
gedatolisib
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT01937715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01937715.